Bertram Pitt

professor of medicine emeritus

University of Michigan Medical School

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Bertram Pitt is a Professor of Medicine Emeritus at the University of Michigan Medical School in the United States. His research primarily focuses on the effects of mineralocorticoid receptor antagonists in cardiovascular and renal health, particularly in relation to hypertension, heart failure, and chronic kidney disease. Recent publications include studies on the impact of finerenone on renal biomarkers and its implications for patient care in various hypertensive conditions.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

george bakris

Professor of medicine, Director AHA Comprehensive Hypertension Center

University of Chicago

UNITED STATES

View details

Sascha N Goonewardena

University of Michigan

UNITED STATES

View details

Marco Metra

Full Professor of Cardiology

University of Brescia

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Bertram Pitt

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial

Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction

Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease

Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease

Moving Forward by Looking Backwards: The Role of Combination Therapy With a Mineralocorticoid Receptor Antagonist and a Thiazide Diuretic in Patients With Hypertension

Mineralocorticoid receptor antagonists for the prevention of atrial fibrillation in patients with and without heart failure: one more beneficial effect?

Carat, clarity, colour, and cut: grading the DIAMOND trial

What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence

Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry

Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade

Prevention of cardiorenal damage: importance of albuminuria

Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis

Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?

Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19

Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

Collaborators (3)

george bakris

Sascha N Goonewardena

Marco Metra

Make your next move.